Kymera Therapeutics Cuts 2026 Sales Forecast to $42.5M After Q4 Revenue Miss
Kymera Therapeutics expects Q1 2026 revenue of $8.61 million with a loss of $0.88 per share and has slashed full-year 2026 sales estimates from $49.20 million to $42.52 million over the past 90 days. In Q4 2025, revenue fell to $2.87 million—80.9% below expectations—and EPS missed at −$0.97 per share.
1. Q1 2026 Earnings Preview
Kymera will release Q1 results on April 30, 2026, with revenue projected at $8.61 million and EPS loss of $0.88. Full-year 2026 revenue consensus stands at $42.52 million, while full-year EPS forecast is a loss of $3.76 per share.
2. Downward Estimate Revisions
Revenue forecasts for 2026 have been trimmed from $49.20 million to $42.52 million over the past 90 days, while the 2027 outlook has decreased from $50.21 million to $46.00 million. Earnings estimates for both years have also been revised lower, reflecting increased projected operating losses.
3. Q4 2025 Performance Shortfall
In Q4 2025, reported revenue reached $2.87 million, missing estimates by 80.9%, and an EPS loss of $0.97 undercut forecasts by 24.4%. The steep miss underscored challenges in achieving near-term revenue growth.
4. Analyst Price Targets & Ratings
Analysts set an average one-year price target at $118.85, implying a 41.7% upside. A separate valuation model places fair value at $16.39, implying an 80.5% downside from current levels. Broker consensus rating stands at 1.7 (Outperform) on a 1 (Strong Buy) to 5 (Sell) scale.